FOLD Amicus Therapeutics, Inc.

6.27
+0.19  (3.13%)
Previous Close 6.08
Open 6.06
Price To book 2.57
Market Cap 892.38M
Shares 142,326,000
Volume 2,305,239
Short Ratio 8.86
Av. Daily Volume 3,612,250

SEC filingsSee all SEC filings

  1. 8-K - Current report 17616446
  2. 8-K - Current report 17615715
  3. 8-K - Current report 17612930
  4. 8-K - Current report 17611735
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17610614

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Additional trials required following feedback from FDA. Enrollment to commence 2017 with data due in 2019.
Migalastat HCl monotherapy (012)
Fabry Disease
"Phase 3 top-line data due mid 2017.
SD-101
Epidermolysis Bullosa (EB)
Phase 1/2 additional data released February 15, 2017.
ATB200
Pompe Disease

Latest News

  1. AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  2. Amicus Therapeutics Presents Additional Positive Preliminary Phase 1/2 Data at WORLDSymposium™ 2017
  3. Amicus Therapeutics Updates Migalastat Drug
  4. AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  5. Amicus Therapeutics Presents Important New Scientific Findings and Preclinical Data for Pompe Program at WORLDSymposium™ 2017
  6. Amicus Therapeutics Highlights New Fabry Program Data at WORLDSymposium™ 2017
  7. AMICUS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
  8. Amicus Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference
  9. Biotech Premarket Movers: Amicus Therapeutics, Nantkwest and Organovo
  10. Amicus Therapeutics Announces Presentations and Posters at 13th Annual WORLDSymposium™ 2017
  11. Amicus Therapeutics upgraded by Robert W. Baird
  12. Amicus Therapeutics Provides Full-Year 2017 Strategic Outlook and Financial Guidance
  13. AMICUS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure,
  14. Huge Energy Trade Kicks Off 2017 Insider Buying: DCP Midstream, Och-Ziff Capital, TransEnterix, Amicus Therapeutics and More
  15. National Institute for Health and Care Excellence (NICE) Issues Final Positive Recommendation for Galafold™ (migalastat) for Fabry Disease in England
  16. 5 Stocks Insiders Love Right Now
  17. AMICUS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
  18. Amicus Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
  19. Abercrombie, OvaScience Slide Into Thursday’s 52-Week Low Club
  20. Amicus Therapeutics, Inc. (FOLD) Announces The Closure Of Its Senior Convertible Notes
  21. AMICUS THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Def
  22. Amicus Therapeutics Announces Closing of Offering of Senior Convertible Notes and Exercise in Full of Option to Purchase Additional Notes
  23. Amicus Therapeutics Announces Closing of Offering of Senior Convertible Notes and Exercise in Full of Option to Purchase Additional Notes
  24. Amicus Therapeutics Announces Pricing of Offering of Convertible Senior Notes
  25. Amicus Therapeutics to Announce Second Quarter 2016 Financial Results on August 9, 2016
  26. Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
  27. Amicus' Fabry disease drug gets European Commission approval
  28. Amicus Therapeutics to Announce First Quarter 2016 Financial Results on May 3, 2016
  29. Amicus Therapeutics to Announce First Quarter 2016 Financial Results on May 3, 2016
  30. Amicus Therapeutics Receives Positive CHMP Opinion for Approval of Migalastat in Patients with Fabry Disease in European Union
  31. Amicus Therapeutics Announces Expanded Access Program for Migalastat